Polysaccharide Conjugate Platform for Precision Cancer Therapy.

Targeted Drug Delivery Systems
Precise drug delivery with significant reduction of side effects

Every year, 10 million people die from cancer. Cancer is the second most common cause of death worldwide. Cancers affect people around the globe, and their numbers continue to rise, posing a huge challenge to healthcare systems. Despite advances in diagnosis and treatment, many types of cancer remain difficult to cure, and current therapies are often associated with severe side effects. Given the prevalence of this condition, there is a huge demand for effective and safe cancer treatments. At NanoVelos, we strive to meet this need by harnessing the potential of nanotechnology.

Our Mission

NanoVelos’ mission is to revolutionize cancer therapies by utilizing polysaccharide carriers that precisely deliver drugs to diseased tissues. We believe that our innovative technology will enhance the effectiveness of treatments and improve the quality of life for patients.

Strategy

We focus on developing innovative solutions for cancer treatment using polysaccharide carrier technology. Currently, we are working on creating an effective drug using epirubicin (PolEpi), which will be used in ovarian cancer therapy with increased precision and minimal impact on the health of patients.

Strategy

We focus on developing innovative solutions for cancer treatment using polysaccharide carrier technology. Currently, we are working on creating an effective drug using epirubicin (PolEpi), which will be used in ovarian cancer therapy with increased precision and minimal impact on the health of patients.

About Us

NanoVelos is a modern biotechnology company specializing in the use of nanotechnology in oncological therapies. Our team of experienced and dedicated specialists in chemistry, pharmacy, biology, biotechnology, and nanotechnology has developed innovative drug carriers based on dextran. These carriers enable more precise delivery of cancer drugs, thereby reducing the negative effects of the drugs on the body. Our goal is to harness the potential of these carriers to increase the effectiveness of treatment and improve the quality of life for patients worldwide.

Menagement

Piotr Mierzejewski

Vice CEO

Piotr Mierzejewski

Vice CEO

A medical doctor specializing in clinical pharmacology, former advisor to the Minister of Health on pharmaceutical policy. He negotiated Poland’s accession to the EU in the field of pharmaceuticals and was responsible for implementing EU directives in pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products. Owner of a consulting firm collaborating with international pharmaceutical companies on introducing new technologies to the Polish market.

Przemysław Mazurek

CEO

Przemysław Mazurek

CEO

Linked to the healthcare market since 2004. As Managing Director, he restructured and developed the most dynamic Medical Center in the Podkarpacie region, setting new standards for customer service quality in the market. Co-founder of the first online doctor appointment booking solution in Poland. Co-founder of the first and only Infertility Treatment Clinic in Podkarpacie (MEDICOR), which he led as President until 2009. Responsible for the development of health insurance within the PZU Group. As Vice President of PZU Pomoc S.A., he created the largest medical TPA (Third-Party Administrator) in Poland for health insurance services. Co-founder of the first pharmaceutical insurance in Poland. Since 2015, he has been involved in Wealth Management and advises on management and finance. Graduate of International Economic and Political Relations and Management and Marketing at the Warsaw School of Economics, as well as the Advanced Management Program at IESE Business School – University of Navarra in Spain.

Supervisory Board

Stefan Bogusławski

Member of the Supervisory Board

Stefan Bogusławski

Member of the Supervisory Board

Dr. Stefan Bogusławski has been conducting research and consulting in the broad field of healthcare for almost 30 years. His professional experience includes many years of leadership at Sequence and PEX PharmaSequence – Polish advisory and research companies specializing in the healthcare market, as well as managing the Polish branch and the Central European region at IMS Health (now IQVIA) and the research company Azyx Polska. He is the author of numerous presentations at conferences in Poland and abroad, as well as publications in both general and specialized media on the Polish healthcare market, particularly the pharmaceutical market. A graduate of the Medical University of Warsaw, he obtained his medical degree in 1985. He has participated in numerous domestic and international courses and training in general management (including INSEAD), finance, marketing, communication, sales skills, and human resource management. Stefan Bogusławski also works as a senior specialist at the Department of Monitoring and Analysis of the Health Status of the Population at the National Institute of Public Health – PZH – PIB. He has been repeatedly included in the “Top 100 Most Influential People in the Polish Healthcare System” list, published by Puls Medycyny.

Robert Dziubłowski

Member of the Supervisory Board

Robert Dziubłowski

Member of the Supervisory Board

Co-founder of Top Consulting S.A., one of the oldest consulting companies in the Polish market. He has over 25 years of international experience in investment consulting, capital raising for companies, market acquisitions, and company management. For many years, he was a consultant for American financial organizations on Wall Street in New York, including those listed on the NASDAQ and NYSE stock exchanges. He has advised, among others: Household International in preparing acquisition strategies and obtaining a banking license in Poland, Wussler Group, Ted Turner Pictures’ partner in attempting to acquire NTV, the largest private TV station in Russia, Eiffage Construction in acquiring Mitex, the largest construction company at the time, and Industrial Union of Donbas, an industrial group in Ukraine. He has been a member, chairman, and president of the supervisory boards of numerous companies listed on the Warsaw Stock Exchange, including Bauma S.A. (now ULMA S.A.), Computerland Poland S.A. (now Signity), and PolAqua S.A. He is also a co-founder of the Start-up Hub Poland Fund. He graduated from the Faculty of Journalism and Political Science at the University of Warsaw and International Relations at the University of Hawaii in Honolulu.

Jerzy Garlicki

Chairman of the Supervisory Board

Jerzy Garlicki

Chairman of the Supervisory Board

A medical doctor who also completed an MBA, an effective manager. Organizer of business models and company structures – experienced in building and developing companies as well as leading corporate restructuring processes. Former director and motivator of large companies and teams. Recognized as a leader in the Polish pharmaceutical industry. Member of the Supervisory Board of American Heart of Poland SA and President of WSiP SA. Previously, President of AstraZeneca Sp. z o.o., President of Fournier Polska Sp. z o.o., Sales Director at Pfizer Polska Sp. z o.o., Sales Director and Marketing Director at MSD Poland – also involved in clinical research.

Technology

NanoVelos technology is based on an innovative polysaccharide platform derived from dextran, effectively serving as a carrier for precise drug delivery. Thanks to a pH-dependent binding mechanism, therapeutic substances are selectively released in cancer cells, enhancing treatment efficacy while simultaneously reducing side effects. Toxic drug components accumulate within the diseased tissues rather than spreading throughout the entire body, significantly improving the safety profile of the therapy.

Our carriers are synthesized without the use of metal particles or toxic substances, ensuring exceptional safety and biocompatibility. Additionally, their structure allows for the attachment of other substances. Thanks to patented technology, protected in many countries, NanoVelos offers a solution with vast potential applications.

Nanotechnology is becoming one of the key directions in the development of modern medicine, and NanoVelos is setting new standards in this field. Our innovative approach to drug delivery opens new therapeutic possibilities, offering hope for more effective and safer treatment methods for patients worldwide.

Partners

Grants

17 April, 2025

Preclinical and Clinical Studies of Innovative Nanoformulations of Anticancer Drugs

Career

Do you set ambitious scientific goals for yourself? Are you interested in participating in medical projects in the fields of biotechnology and nanotechnology?

NanoGroup is a platform for expertise and specialists united by the belief that breakthrough technologies addressing pressing global challenges can be created and developed in Poland.

If you’d like to join our team, get in touch with us!

Join the team

Get in Touch

NanoVelos
ul. Rakowiecka 36
02-532 Warszawa
NIP: 9522123769
REGON: 146595247
KRS: 0000581695

Office
+48 604 741 303

District Court for the Capital City of Warsaw, 13th Commercial Division of the National Court Register KRS: 0000581695, Share Capital (fully paid) 1,004,320.80 PLN

pp-thumbnail